Screening for viral hepatitis B infection in cancer patients before receiving chemotherapy – A systematic review and meta‐analysis

Abstract

AbstractAimWe conducted a systematic review and meta‐analysis to assess the hepatitis B virus (HBV) screening rate in cancer patients before systemic chemotherapy, aiming to identify those needing antiviral prophylaxis for HBV reactivation.MethodsWe searched PubMed, Embase, Scopus, and Google Scholar for relevant studies. The pooled screening rate was estimated using a random effects model. Subgroup analyses were conducted based on malignancy types, chemotherapy regimens, study period, and HBV endemic regions.ResultsThe meta‐analysis included 29 studies from various endemic regions (19 low‐endemic, three lower intermediate‐endemic, and seven higher intermediate‐endemic). These studies encompassed hematologic malignancies (n = 10), solid‐organ tumors (n = 4), and combinations (n = 15). Seven studies used rituximab‐containing regimens, four did not, and the remaining 11 did not specify chemotherapy regimens. The pooled screening rate was 57% (95% confidence interval [95%CI]: 46%–68%, I2 = 100%). Over time, screening rates improved from 37% (95%CI: 23%–53%) in 2006–2010 to 68% (54%–80%) in 2011–2015 and 69% (48%–84%) in 2016–2020. Screening rates were highest at 89% (74%–96%) in high endemic countries, followed by 60% (45–73%) in lower‐intermediate and 49% (34–64%) in low‐endemic countries. Patients with hematological malignancies had a higher screening rate than those with solid organ tumors, 65% (55%–74%) versus 37% (21%–57%), respectively. A screening rate was higher in patients receiving rituximab‐containing chemotherapy than non‐rituximab regimens, 68% (55%–79%) versus 45% (27%–65%).ConclusionDespite existing guidelines, pre‐chemotherapy HBV screening rate remains unsatisfactory, with substantial heterogeneous rates globally. These findings underscore the need for effective strategies to align practices with clinical guidelines.